Pegvisomant in the treatment of acromegaly.
dc.contributor.author | Parkinson, Craig | |
dc.contributor.author | Scarlett, J A | |
dc.contributor.author | Trainer, Peter J | |
dc.date.accessioned | 2009-08-27T14:18:41Z | |
dc.date.available | 2009-08-27T14:18:41Z | |
dc.date.issued | 2003-09-26 | |
dc.identifier.citation | Pegvisomant in the treatment of acromegaly. 2003, 55 (10):1303-14 Adv. Drug Deliv. Rev. | en |
dc.identifier.issn | 0169-409X | |
dc.identifier.pmid | 14499709 | |
dc.identifier.doi | 10.1016/S0169-409X(03)00111-X | |
dc.identifier.uri | http://hdl.handle.net/10541/78905 | |
dc.description.abstract | Epidemiological studies have highlighted the need for tight control of growth hormone (GH) and insulin-like growth factor I (IGF-I) in patients with acromegaly. Studies highlighting the events involved in GH receptor signaling have allowed the development of a pegylated GH receptor antagonist (pegvisomant) for use in humans, which has been designed to outcompete GH for the GH receptor, but which contains a position 120 amino acid substitution that prevents recruitment of a second GH receptor. This process of receptor dimerisation is crucial for signal transduction and IGF-I generation. Clinical trials of pegvisomant suggest it is the most effective treatment for acromegaly to date, as this therapy is capable of normalising serum IGF-I in up to 97% of patients when doses of 40 mg per day are used. This paper reviews the development of pegvisomant and the clinical experience in patients with acromegaly to date. | |
dc.language.iso | en | en |
dc.subject.mesh | Acromegaly | |
dc.subject.mesh | Human Growth Hormone | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Randomized Controlled Trials as Topic | |
dc.subject.mesh | Receptors, Somatotropin | |
dc.title | Pegvisomant in the treatment of acromegaly. | en |
dc.type | Article | en |
dc.contributor.department | Department of Endocrinology, Christie Hosptial, Wilmslow Road, Manchester M20 4BX, UK. | en |
dc.identifier.journal | Advanced Drug Delivery Reviews | en |
html.description.abstract | Epidemiological studies have highlighted the need for tight control of growth hormone (GH) and insulin-like growth factor I (IGF-I) in patients with acromegaly. Studies highlighting the events involved in GH receptor signaling have allowed the development of a pegylated GH receptor antagonist (pegvisomant) for use in humans, which has been designed to outcompete GH for the GH receptor, but which contains a position 120 amino acid substitution that prevents recruitment of a second GH receptor. This process of receptor dimerisation is crucial for signal transduction and IGF-I generation. Clinical trials of pegvisomant suggest it is the most effective treatment for acromegaly to date, as this therapy is capable of normalising serum IGF-I in up to 97% of patients when doses of 40 mg per day are used. This paper reviews the development of pegvisomant and the clinical experience in patients with acromegaly to date. |